Image

Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

Recruiting
2 - 17 years of age
Both
Phase 2/3

Powered by AI

Overview

Randomized, double-blind, pediatric trial of amisulpride for prophylaxis of post operative nausea and vomiting

Description

Randomized, double-blind, Phase 2/3 study of IV amisulpride as prevention of post-operative nausea and vomiting in pediatric patients

Eligibility

Inclusion Criteria:

  1. Male or female patients aged from full-term birth to 17 years of age
  2. Signed informed consent form and/or assent and willingness of patient and parents to participate in the trial
  3. Patients undergoing non-emergency surgery, preferentially eye surgery, adenotonsillectomy or otoplasty, under general anesthesia (other than total intravenous anesthesia with propofol) expected to last at least 30 minutes from induction of anesthesia to removal of Endotracheal tube (ETT) or Laryngeal mask airway (LMA)
  4. American Society of Anesthesiologists (ASA) risk score I-III
  5. For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (as defined in ICH M3 guidance, e.g., true (not periodic) abstinence from sexual intercourse, surgical sterilization (of subject or partner), combined oral contraceptive pill, or any other method or combination of methods with a failure rate generally considered to be <1% per year) between the date of screening and at least 48 hours after administration of study drug.

Exclusion Criteria:

  1. Patients scheduled to undergo transplant or Central Nervous System (CNS) surgery
  2. Patients scheduled to receive only a local anesthetic and/or regional neuraxial (intrathecal or epidural) block (without general anesthesia) or to receive general anesthesia involving total intravenous anesthesia (TIVA) with propofol
  3. Patients who, in the opinion of the Investigator, are expected to remain ventilated for a significant period after surgery
  4. Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed
  5. Patients who are expected to receive systemic pre/peri-operative corticosteroid therapy other than as anti-emetic prophylaxis
  6. Patients receiving amisulpride for any indication within the 2 weeks prior to randomization
  7. Patients known to be allergic to amisulpride or any of the excipients of amisulpride drug product; or to dexamethasone or ondansetron
  8. Patients with a significant ongoing history of vestibular disease or dizziness
  9. Patients being treated with regular anti-emetic therapy (dosed at least three times per week), which is still ongoing less than 1 week prior to screening
  10. Patients being treated with levodopa, or any other dopamine D2-agonist
  11. Patients who are pregnant or breast feeding
  12. Patients with congenital long QT interval (QT) syndrome
  13. Patients with a tumor of the anterior pituitary
  14. Patients who have received emetogenic anti-cancer chemotherapy in the previous 4 weeks
  15. Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study
  16. Patients who have previously participated in this study or who have participated in another interventional clinical study involving pharmacological therapy within the previous 28 days (or longer exclusion period, if required by national or local regulations)
  17. Where local laws/regulations require: patients under legal protection

Study details

Nausea and Vomiting, Postoperative

NCT05546359

Acacia Pharma Ltd

1 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.